Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR4640 + furosemide is a combination of two pharmaceutical agents. Furosemide is a well-established loop diuretic used to treat edema associated with congestive heart failure, liver disease (cirrhosis), and renal disease (including nephrotic syndrome), as well as hypertension. It acts by inhibiting the reabsorption of sodium and chloride in the loop of Henle and distal renal tubule in the kidney, leading to increased excretion of water and electrolytes such as sodium, chloride, magnesium, potassium, and calcium[1][5][6]. Furosemide is available under several brand names including Lasix and Furoscix. SHR4640 appears to be an investigational or code name for another agent; however, no detailed public information about its mechanism or clinical status was found in these results.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SHR4640 + furosemide.